910 related articles for article (PubMed ID: 22424862)
1. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
Gehrig SM; Ryall JG; Schertzer JD; Lynch GS
Exp Physiol; 2008 Nov; 93(11):1190-8. PubMed ID: 18567600
[TBL] [Abstract][Full Text] [Related]
4. IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death.
Smith J; Goldsmith C; Ward A; LeDieu R
Cell Death Differ; 2000 Nov; 7(11):1109-18. PubMed ID: 11139285
[TBL] [Abstract][Full Text] [Related]
5. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice.
Gregorevic P; Plant DR; Lynch GS
Muscle Nerve; 2004 Sep; 30(3):295-304. PubMed ID: 15318340
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular administration of PEGylated IGF-I improves skeletal muscle regeneration after myotoxic injury.
Martins KJ; Gehrig SM; Naim T; Saenger S; Baum D; Metzger F; Lynch GS
Growth Horm IGF Res; 2013 Aug; 23(4):128-33. PubMed ID: 23608055
[TBL] [Abstract][Full Text] [Related]
7. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
8. A new model of experimental fibrosis in hindlimb skeletal muscle of adult mdx mouse mimicking muscular dystrophy.
Desguerre I; Arnold L; Vignaud A; Cuvellier S; Yacoub-Youssef H; Gherardi RK; Chelly J; Chretien F; Mounier R; Ferry A; Chazaud B
Muscle Nerve; 2012 Jun; 45(6):803-14. PubMed ID: 22581532
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
10. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice.
Schertzer JD; Gehrig SM; Ryall JG; Lynch GS
Am J Pathol; 2007 Oct; 171(4):1180-8. PubMed ID: 17823291
[TBL] [Abstract][Full Text] [Related]
11. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
[TBL] [Abstract][Full Text] [Related]
12. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.
Rafael JA; Tinsley JM; Potter AC; Deconinck AE; Davies KE
Nat Genet; 1998 May; 19(1):79-82. PubMed ID: 9590295
[TBL] [Abstract][Full Text] [Related]
14. Cloning of cDNA encoding a regeneration-associated muscle protease whose expression is attenuated in cell lines derived from Duchenne muscular dystrophy patients.
Nakayama Y; Nara N; Kawakita Y; Takeshima Y; Arakawa M; Katoh M; Morita S; Iwatsuki K; Tanaka K; Okamoto S; Kitamura T; Seki N; Matsuda R; Matsuo M; Saito K; Hara T
Am J Pathol; 2004 May; 164(5):1773-82. PubMed ID: 15111323
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
Schertzer JD; Ryall JG; Lynch GS
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery.
Abmayr S; Gregorevic P; Allen JM; Chamberlain JS
Mol Ther; 2005 Sep; 12(3):441-50. PubMed ID: 16099410
[TBL] [Abstract][Full Text] [Related]
17. Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.
van Putten M; Kumar D; Hulsker M; Hoogaars WM; Plomp JJ; van Opstal A; van Iterson M; Admiraal P; van Ommen GJ; 't Hoen PA; Aartsma-Rus A
Neuromuscul Disord; 2012 May; 22(5):406-17. PubMed ID: 22284942
[TBL] [Abstract][Full Text] [Related]
18. Weekly oral prednisolone improves survival and strength in male mdx mice.
Keeling RM; Golumbek PT; Streif EM; Connolly AM
Muscle Nerve; 2007 Jan; 35(1):43-8. PubMed ID: 16969833
[TBL] [Abstract][Full Text] [Related]
19. Expression of full-length utrophin prevents muscular dystrophy in mdx mice.
Tinsley J; Deconinck N; Fisher R; Kahn D; Phelps S; Gillis JM; Davies K
Nat Med; 1998 Dec; 4(12):1441-4. PubMed ID: 9846586
[TBL] [Abstract][Full Text] [Related]
20. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
